POM-V Prescription Required Companion Animal

Prevomax 10 mg/ml Solution for Injection for Dogs and Cats

Active ingredient: Maropitant

Form

Injection

Species

Cats Dogs

Manufacturer

Dechra Regulatory B.V.

VMD MA No.

50406/5002

What it's used for

Cats • induced by motion sickness. •

Full indications, dosage and side effects ↓

View official SPC (PDF)

The prescription itself has a price. See what practices near you charge for a consultation and the written prescription fee.

Paying less for Maropitant

1

Ask your vet for a written prescription

They must provide one on request. Under the CMA Order the fee is capped at £21 from 2027.
2

Fill it at a registered online retailer

The CMA found online pharmacies 50–60% cheaper than practice dispensing on common medicines — typically £200–£300 a year.

Your prescription rights → VMD register of retailers →

Prescription required

Your vet must provide a written prescription on request. You can then purchase from any licensed online retailer.

Clinical information

Prevomax 10 mg/ml Solution for Injection for Dogs and Cats — SPC Details

Source: VMD Summary of Product Characteristics (SPC). Last updated 27 Mar 2026.

Cats
•
induced by motion sickness.
•

The veterinary medicinal product solution for injection should be injected
subcutaneously or intravenously, once daily, at a dose of 1 mg of maropitant / kg
bodyweight (1 ml/10 kg bodyweight) for up to 5 consecutive days. Intravenous
administration of the veterinary medicinal product should be given as a single bolus
without mixing the product with any other fluids.
To prevent vomiting, the veterinary medicinal product solution for injection should be
administered more than 1 hour in advance. The duration of effect is approximately 24
h and therefore treatment can be given the night before administration of an agent
that may cause emesis e.g. chemotherapy.
As the pharmacokinetic variation is large and maropitant accumulates in the body
after once daily repeated administration, lower doses than recommended might be
sufficient in some individuals and when repeating the dose.
For administration by subcutaneous injection, see also “special precautions for safe
use in the target species” (section 3.5).

None.

Target species: Dog, cat
Very common
(>1 animal / 10 animals treated):
Injection site pain
a
Very rare
(<1 animal / 10,000 animals treated,
including isolated reports):
Anaphylactic-type reactions (allergic
oedema, urticaria, erythema, collapse,
dyspnoea, pale mucous membranes)
Lethargy
Ataxia, Convulsion, Seizure, Muscle
tremor
Undetermined frequencyInjection site pain
b
a
in cats - moderate to severe (in approximately one third of cats) when injected
subcutaneously.
b
in dogs - when injected subcutaneously.
Reporting adverse events is important. It allows continuous safety monitoring of a
veterinary medicinal product.
AN: 00587/2025Page 4 of 8
Reports should be sent, preferably via a veterinarian, to either the marketing
authorisation holder or its local representative or the national competent authority
via the national reporting system. See the package leaflet for respective contact
details.

Vomiting can be associated with serious, severely debilitating conditions including
gastrointestinal obstructions; therefore, appropriate diagnostic evaluations should be
employed.
Good veterinary practice indicates that antiemetics should be used in conjunction with
other veterinary and supportive measures such as dietary control and fluid
replacement therapy while addressing the underlying causes of the vomiting.
The use of the veterinary medicinal product against vomiting due to motion sickness
is not recommended.
Dogs:
Although maropitant has been demonstrated to be effective in both the treatment and
prevention of emesis induced by chemotherapy, it was found more efficacious if used
preventively. Therefore, it is recommended to administer the veterinary medicinal
product prior to administration of the chemotherapeutic agent.
Cats:
The efficacy of maropitant in reduction of nausea was demonstrated in studies using
a model (xylazine-induced nausea).

Special precautions for safe use in the target species:
The safety of maropitant has not been established in dogs less than 8 weeks of
age, or in cats less than 16 weeks of age, and in pregnant or lactating dogs and
cats. Use only according to the benefit-risk assessment by the responsible
veterinarian.
Maropitant is metabolised in the liver and therefore should be used with caution in
patients with hepatic disease.
AN: 00587/2025Page 3 of 8
As maropitant is accumulated in the body during a 14 day treatment period due to
metabolic saturation, careful monitoring of liver function and any adverse events
should be implemented during long term treatment.
The veterinary medicinal product should be used with caution in animals suffering
from or with predisposition for cardiac diseases as maropitant has affinity to Ca- and
K-ion channels. Increases of approximately 10% in the QT interval of the ECG were
observed in a study on healthy Beagle dogs administered 8 mg/kg orally; however,
such an increase is unlikely to be of clinical significance.
Due to the frequent occurrence of transient pain during subcutaneous injection,
appropriate animal restraining measures may have to be applied. Injecting the
product at refrigerated temperature may reduce pain at injection.
Special precautions to be taken by the person administering the veterinary
medicinal product to animals:
People with known hypersensitivity to maropitant should administer the veterinary
medicinal product with caution.
Wash hands after use. In case of accidental self-injection seek medical advice
immediately and show the package leaflet or the label to the physician. In laboratory
studies, maropitant has been shown to be a potential eye irritant. In the case of
accidental eye exposure, flush the eyes with plenty of water and seek medical
attention.
Special precautions for the protection of the environment:
Not applicable.

The veterinary medicinal product should not be used concomitantly with Ca-channel
antagonists as maropitant has affinity to Ca-channels.
Maropitant is highly bound to plasma proteins and may compete with other highly
bound medicines.

Do not freeze.

Not applicable.

This information is sourced from the official Summary of Product Characteristics (SPC) published by the Veterinary Medicines Directorate (VMD). It is provided for informational purposes only and does not replace professional veterinary advice. Always consult your vet before administering any medication.